Therapies of the future: Targeting non-coding RNA with small molecules

At Saverna Therapeutics we use a platform based on the latest Artificial Intelligence tools and Nuclear Magnetic Resonance to reduce the time and costs of drug discovery.

Discover More

About us

Company

Saverna Therapeutics was founded 2017 with a mission to change the way pharmaceutical companies discover and develop safe, orally active small molecules that target non-coding RNA-biology to treat diseases with unmet medical need.

Discover More

Purpose

Science

Saverna Therapeutics aims to discover highly active, selective and cell-permeable low molecular weight molecules that target RNA biology.

Discover More

Investors

Sharing Discoveries

Saverna Therapeutics to date has been financed through a mixture of self-funding, grant awards from Switzerland and Europe via Innosuisse and Eurostars programs.

Discover More

News & Press

Latest News

Meet us at RESI ASIA, 12-14 November, Shanghai & Taipei

The Redefining Early Stage Investments (RESI) conference series will provide LSN’s global tribe of early-stage entrepreneurs and investors with a venue to meet face to face with partners from China, Taiwan, and other key Pacific Rim life science hubs.

Meet us at the 4th Drug Discovery Strategic Summit, 17-18 October, Munich

The 4th Drug Discovery Strategic Summit highlights the advances in current and emerging hot targets and technologies.

Meet us at Targeting RNA, 26-27 November, Frankfurt

The Targeting RNA congress will present the latest breakthroughs in modulation of RNA (splicing/non-coding/micro) directly with small molecules and through epigenetics.